ReviewCurrent urology reports2019
Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
Review in Current urology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Renal Medullary Carcinoma: Utility of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Potential of Metabolic MRI to Address Unmet Clinical Needs in Localised Kidney Cancer.Cancers · 2025Review
- K-Means Clustering of HyperpolarisedCancers · 2025Article
- The Utility ofMolecular imaging and radionuclide therapy · 2025Article
- The role of [European journal of nuclear medicine and molecular imaging · 2024Article
- Radiogenomics in Renal Cancer Management-Current Evidence and Future Prospects.International journal of molecular sciences · 2023Review
- Review
- [Imaging of oligometastatic disease in selected urologic cancers].Der Urologe. Ausg. A · 2021Review
- Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma.Cancers · 2021Article
- Article
- Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo.Scientific reports · 2020Article
- Role of positron emission tomography/computed tomography in the evaluation of renal cell carcinoma.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe clinical role of fluorine-18 fluoro-2-deoxyglucose (FDG)-positron emission tomography (PET) in renal cell carcinoma (RCC) is still evolving. Use of FDG PET in RCC is currently not a standard investigation in the diagnosis and staging of RCC due to its renal excretion. This review focuses on the clinical role and current status of FDG PET and PET/CT in RCC. RECENT
findingsStudies investigating the role of FDG PET in localized RCC were largely disappointing. Several studies have demonstrated that the use of hybrid imaging PET/CT is feasible in evaluating the extra-renal disease. A current review of the literature determines PET/CT to be a valuable tool both in treatment decision-making and monitoring and in predicting the survival in recurrent and metastatic RCC. PET/CT might be a viable option in the evaluation of RCC, especially recurrent and metastatic disease. PET/CT has also shown to play a role in predicting survival and monitoring therapy response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.